<DOC>
	<DOCNO>NCT03020901</DOCNO>
	<brief_summary>1 . Primary study endpoint Security Effectiveness 2 . Secondary study endpoint Extensive use population characteristic Clinical drug characteristic appropriate crowd characteristic Adverse reaction susceptible population characteristic Reveal rare , new , unanticipated long-term adverse drug reaction bacterial resistance Explore advantage teicoplanin combination antimicrobial agent Explore opportunistic use teicoplanin injection</brief_summary>
	<brief_title>Clinical Trial Teicoplanin Injection</brief_title>
	<detailed_description>Research purpose 1 . To explore safety efficacy different dos teicoplanin injection real world 2 . To explore characteristic different dos teicoplanin injection , clinical characteristic drug use repeat use bacterial resistance ; 3 . Reveal rare even rare , new , unanticipated , adverse drug reaction associate long-term use ; 4 . To explore advantage different dos teicoplanin combination antimicrobial agent ; 5 . To explore use teicoplanin treatment infectious disease rational use drug time ; 6 . To reveal risk factor adverse reaction susceptibility people , identify characteristic crowd ; 7 . To investigate clinical use teicoplanin injection real situation , risk management , expand indication expert consensus dose study provide clinical clue basis ; 8 . To provide reference revision clinical guideline consensus , clinical pathway design ; 9 . To enhance level safe use teicoplanin injection , basic medical support market vitality . Research design 1 . National , large-scale , standardized , standardized , real-world research ; 2 . Prospective , single - arm open , non - interventional , registration , multi - center clinical study ; 3 . In hospital use teicoplanin injection , 200 select basis voluntary principle ; 4 . Registration teicoplanin patient injection ; 5 . Target sample size 100,000 case ; 6 . Exemption inform consent ethical review application ; 7 . Study teicoplanin large-scale data safety effectiveness antibiotic .</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>Prescription teicoplanin patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>